This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Tizanidine
From PsychonautWiki Archive
Revision as of 19:07, 8 April 2022 by >Goornie(added external link)
It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Tizanidine (known by the trade names Zanaflex and Trinex among others) is a depressant substance of the imidazoline class closely related to clonidine. Tizanidine is primarily used primarily as an antispasmodic drug. Tizanidine's effectivness is similar to that of baclofen or diazepam[1].
Tizanidine is a central α2 adrenergic agonist. The relationship between the α2 receptor agonism and the spasmolytic function of tizanidine is not fully understood [2] .
While recreational use is extremely rare, some users take tizanidine for its standalone sedative effects or to potentiate the effects of opiates. In higher doses, tizanidine is capable of inducing hallucinations, psychosis, and delirium[3].
Tizanidine is 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at α2-adrenergic receptor sites. It is a benzothiadiazole and a member of imidazoles[4].
Pharmacology
Tizanidine is an imidazoline derivative and centrally acting α2 adrenergicagonist closely related to Clonidine. Tizanidine inhibits the release of excitatory amino acids from spinal interneurons. As a result, Tizanidine enhances the presynaptic inhibition of motor neurons.
Tizanidine also has some affinity for the α1 receptors, but to a lesser than Clonidine, which may explain why its cardiovascular effects are so much milder than that of Clonidine[5]. Tizanidine has approximately one tenth to one fifteenth of the blood pressure lowering effect of clonidine [6] .
Tizanidine has also been found to have anticonvulsant effects against strychnine-induced seizures but not against GABA-induced seizures. The α2 receptor mediated inhibition of inter-neuronal activity appears to be the cause of Tizanidine's anti-convulsant properties [7] .
Tizanidine has an oral bioavailability of 20-34% and an elimination half-life of 2.5 hours. It attains steady-state concentration within 24-48 hours after administration [8]
The table below compares the selectivity of Tizanidine and other drugs to the imidzaoline-receptor and the α2 receptors in rats. Tizanidine has a significantly greater selectivity to the imidazoline receptor than clonidine. The imidazoline receptor selectivity of tizanidine may be responsible for its unique pharmacological profile[9].
Drug
Imidazoline receptors Ki (nM)
α2 Receptors Ki (nM)
Tizanidine
4.17 ± 1.81
91.5 ± 9.1
Clonidine
9.20 ± 1.23
9.20 ± 1.23
Oxymethazoline
2.28 ± 0.36
25.9 ± 5.5
Naphazoline
309 ± 26
25.9 ± 5.5
Adrenaline
> 10000
3.18 ± 0.41
Subjective effects
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Seizure suppression - Tizanidine has been found to suppress strycnine induced seizures, but not GABA induced seizures.
Sedation - Tizanidine can produce a strong sedative effect. Users can become very tired and sleep through stimuli that would otherwise wake them.
At high doses, geometry can be observed likely due to experiencing low blood pressure and circulation to the brain. The geometry is distinct from psychedelic and dissociative drugs. It can be described as intricate in complexity, abstract in form, synthetic in feel, unstructured in organization, dimly lit, multicolored in scheme, flat in shading, soft in edges, smooth in motion, slow in speed, small in size, angular in corners, non-immersive in depth, and consistent in intensity.
The geometry of Tizanidine never exceeds level 4. The doses required to observe such geometries can induce dangerously low blood pressures and cause one to lose consciousness. Users should exercise caution when taking hallucinogenic doses, as the threshold for hallucinations is not far from the threshold for psychosis in many users.
Hallucinatory states
In higher doses, Tizanidine is capable of inducing a delirious state.
Soreness - After the effects of tizanidine wear off, muscles that weren't sore before using the drug can become sore with more ease. For most users, this first presents itself as an increased soreness in the neck.
Experience reports
There are currently 0 experience reports which describe the effects of this substance in our experience index.
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.
While no long term studies of tizanidine use in humans have been done, studies done in animals indicate no signs of long term carcinogenicity. However, tizanidine has been shown to have a developmental effect on young rats[10].
Some long term tizanidine use has been attributed to liver problems and in extreme cases, liver failure and death[11].
Lethal dosage
The LD50 of oral tizanidine in rats was found to be 414mg/kg in rats and 235 mg/kg in mice[12].
Tolerance and addiction potential
While dependence is rare, use of Tizanidine exceeding 36mg daily over an extended period of time can lead to hypertensive withdrawals. In cases where dependence has been built, a user should taper to avoid a hypertensive crisis[13].
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Dissociatives - This combination can unpredictably potentiate the amnesia, sedation, motor control loss and delusions that can be caused by each other. It may also result in a sudden loss of consciousness accompanied by a dangerous degree of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Stimulants - Stimulants mask the sedative effect of depressants, which is the main factor most people use to gauge their level of intoxication. Once the stimulant effects wear off, the effects of the depressant will significantly increase, leading to intensified disinhibition, motor control loss, and dangerous black-out states. This combination can also potentially result in severe dehydration if one's fluid intake is not closely monitored. If choosing to combine these substances, one should strictly limit themselves to a pre-set schedule of dosing only a certain amount per hour until a maximum threshold has been reached.
"Tizanidine". Drug Information Portal. U.S. National Library of Medicine.
References
↑ Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52. doi: 10.2165/00003495-199753030-00007. PMID: 9074844.
↑ Katzung, Bertram G. (30 November 2017). Basic & clinical pharmacology. Katzung, Bertram G. (Fourteenth ed.). New York. p. 487. ISBN 9781259641152. OCLC 1015240036
↑ Ghanavatian S, Derian A. Tizanidine. [Updated 2021 Aug 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519505/
↑ Katzung, Bertram G. (30 November 2017). Basic & clinical pharmacology. Katzung, Bertram G. (Fourteenth ed.). New York. p. 487. ISBN 9781259641152. OCLC 1015240036
↑ Denizbaşi A, Berkman K, Ozyazgan S, Eşkazan E. The effect of tizanidine on maximal electroshock seizures (MES) in mice. Gen Pharmacol. 1999 Apr;32(4):513-6. doi: 10.1016/s0306-3623(98)00249-3. Erratum in: Gen Pharmacol 2000 Jun;34(6):443. PMID: 10323494.
↑Ghanavatian S, Derian A. Tizanidine. [Updated 2021 Aug 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519505/
↑Muramatsu I, Kigoshi S. Tizanidine may discriminate between imidazoline-receptors and alpha 2-adrenoceptors. Jpn J Pharmacol. 1992 Aug;59(4):457-9. doi: 10.1254/jjp.59.457. PMID: 1331591.. Retrieved from https://pubmed.ncbi.nlm.nih.gov/1331591/
↑ Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tizanidine. [Updated 2017 Jan 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548048/